ClinicalTrials.gg
CompletedNCT02442349AURA17Updated Jan 9, 2026Results posted

Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific

A Phase 2 interventional study of AZD9291 in Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Completed at 30 sites in 3 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
171
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
19th of 90
171 · median 51
Started
2015
with 4 others
Phase 2
46 of 90
12 open now
Registered
14th of 90
by date
Lead sponsor
29 of 90
AstraZeneca

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 19th largest by enrollment, is one of 5 that started in 2015, is one of 46 in phase 2, and was the 14th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients with Locally Advanced/Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene

Read the detailed description

This is a phase II, open label, single arm study assessing the safety and efficacy of AZD9291 (80 mg, orally, once daily) in Asia Pacific patients with a confirmed diagnosis of Epidermal Growth Factor Receptor (EGFR) sensitising mutation positive (ie, G719X, exon 19 deletion, L858R, L861Q) and T790M mutation positive (hereafter referred to as EGFRm+ and T790M+) un-resectable, locally advanced or metastatic NSCLC (Stage IIIB-IV), who have progressed on an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor(EGFR-TKI), either as first line treatment or following one line of EGFR-TKI and one line of platinum containing doublet chemotherapy. Patients must agree to provide a biopsy for central confirmation of T790M mutation status following confirmed disease progression on the most recent treatment regimen. The primary objective of the study is to assess the efficacy of AZD9291 by assessment of Objective Response Rate according to RECIST 1.1 by an Independent Central Review.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Phase II, Open Label, Single-arm study, Safety and Efficacy of AZD9291, Asia Pacific, NSCLC with T790M mutation within the Epidermal Growth Factor Receptor Gene
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged at least 18 years. Patient from Asia Pacific will be enrolled only.
  • Locally advanced or NSCLC, not amenable to curative surgery or radiotherapy.
  • Radiological documentation of disease progression on the last treatment administered prior to enrolling in the study: following EGFR TKI treatment but who have not received further treatment OR following prior therapy with an EGFR TKI and a platinum-based doublet chemotherapy. Patients may have also received additional lines of treatment.
  • Documented EGFR mutation (at any time since the initial diagnosis of NSCLC) known to be associated with EGFR TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).
  • Patients must have central confirmation of tumour T790M mutation positive status from a sample taken after confirmation of disease progression on the most recent treatment regimen.
  • World Health Organisation (WHO) performance status 0-1 with no deterioration over the previous 2 weeks and a minimum of 12 weeks.
  • At least one lesion, not previously irradiated and not chosen for biopsy during the study screening period, that can be accurately measured at baseline as ≥10mm in the longest diameter (except lymph nodes which must have short axis ≥15mm) with computerised tomography (CT) or magnetic resonance imaging (MRI) which is suitable for accurate repeated measurements.
  • Females of using and must have a negative pregnancy test.

Exclusion criteria

Exclusion Criteria:

  • Treatment with an EGFR-TKI (eg, erlotinib, gefitinib, icotinib or afatinib) within 8 days or approximately 5x half-life of study entry; any cytotoxic chemotherapy, agents or other anticancer drugs within 14 days of study entry; previous treatment with AZD9291 or a 3rd generation EGFR TKIs; Major surgery within 4 weeks of study entry; radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of study entry; currently receiving treatment with potent inhibitors or inducers of .
  • Any unresolved toxicities from prior therapy.
  • Unstable spinal cord compression or .
  • Severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses or infection.
  • nausea and vomiting, chronic gastrointestinal diseases or bowel resection.
  • Cardiac disease.
  • Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required treatment, or any evidence of clinically active interstitial lung disease.
  • Inadequate bone marrow reserve or organ function.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    AZD9291

    Once daily tablet 80 mg

    Drug: AZD9291

Interventions

06

What researchers measure

Primary outcomes

  1. ORR According to RECIST 1.1 by Independent Review

    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (according to independent review) that was confirmed at least 4 weeks later, prior to progression or further anti-cancer therapy.

    Time frame: At baseline and every 6 weeks from time of first dose until objective disease progression,up to 24 months after Last Patient First Dose(LPFD)

Secondary outcomes

  1. DoR According to RECIST 1.1 by Independent Review

    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. DoR was defined as the time from the date of first documented response (CR or PR that was subsequently confirmed) until the date of documented progression (PD) or death in the absence of disease progression (by investigator assessment).

    Time frame: At baseline and every 6 weeks from time first dose until date of progression, up to 24 months after LPFD.

  2. DCR According to RECIST 1.1 by Independent Review

    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions; Stable disease (SD): Neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; Progressive Disease (PD): \>= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of \>=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. DCR is the percentage of patients with best response of CR, PR or SD (according to independent review), prior to progression (PD) or further anti-cancer therapy.

    Time frame: At baseline and every 6 weeks from time first dose until date of progression, up to 24 months after Last Patient First Dose(LPFD)

  3. Tumour Shrinkage According to RECIST 1.1 by Independent Review

    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Tumour size was calculated as the sum of the longest diameters (SLD) of the Target Lesions. Tumour shrinkage is the best percentage change in tumour size from baseline using RECIST v1.1 tumour response.

    Time frame: At baseline and every 6 weeks from time of first dose until date of progression, up to 24 months after LPFD.

  4. PFS According to RECIST 1.1 by Independent Review

    Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Progressive Disease (PD): \>= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of \>=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. PFS is the time from date of first dose until the date of PD (by independent review) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from AZD9291 therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST 1.1 assessment.

    Time frame: At baseline and every 6 weeks from time of first dose until objective disease progression, up to 24 months after LPFD.

  5. Overall Survival (OS)

    Defined as the time from first dose until death from any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.

    Time frame: From first dose to end of study or date of death from any cause, whichever comes first, assessed every 6 weeks up to approximately 95 OS events (about 55% maturity) have been observed out of all enrolled patients.

07

Results

Posted Apr 25, 2017

Participant flow

First patient enrolled: 22 June 2015, The study was open for enrollment at 31 study centres in China (24 sites), South Korea (4 sites), and Australia (3 sites)

Participant flow — Overall Study
MilestoneAZD9291
Started171
Completed46
Not completed125
Withdrew: Death95
Withdrew: Withdrawal by subject27
Withdrew: Poor compliance after treatment discontinuation2
Withdrew: Lost to follow-up1

Outcome measures

PrimaryORR According to RECIST 1.1 by Independent Review

Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. ORR is the percentage of patients with at least 1 visit response of CR or PR (according to independent review) that was confirmed at least 4 weeks later, prior to progression or further anti-cancer therapy.

Time frame:
At baseline and every 6 weeks from time of first dose until objective disease progression,up to 24 months after Last Patient First Dose(LPFD)
Reported as:
Number · % of participants
ORR According to RECIST 1.1 by Independent Review
% of participantsAZD9291
ORR According to RECIST 1.1 by Independent Review62.0 (54.2 to 69.5)
SecondaryDoR According to RECIST 1.1 by Independent Review

Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions. DoR was defined as the time from the date of first documented response (CR or PR that was subsequently confirmed) until the date of documented progression (PD) or death in the absence of disease progression (by investigator assessment).

Time frame:
At baseline and every 6 weeks from time first dose until date of progression, up to 24 months after LPFD.
Reported as:
Median · Months
DoR According to RECIST 1.1 by Independent Review
MonthsAZD9291
DoR According to RECIST 1.1 by Independent Review9.9 (8.3 to 12.9)
SecondaryDCR According to RECIST 1.1 by Independent Review

Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions; Stable disease (SD): Neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; Progressive Disease (PD): \>= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of \>=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. DCR is the percentage of patients with best response of CR, PR or SD (according to independent review), prior to progression (PD) or further anti-cancer therapy.

Time frame:
At baseline and every 6 weeks from time first dose until date of progression, up to 24 months after Last Patient First Dose(LPFD)
Reported as:
Number · % of participants
DCR According to RECIST 1.1 by Independent Review
% of participantsAZD9291
DCR According to RECIST 1.1 by Independent Review88.0 (82.0 to 92.5)
SecondaryTumour Shrinkage According to RECIST 1.1 by Independent Review

Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Tumour size was calculated as the sum of the longest diameters (SLD) of the Target Lesions. Tumour shrinkage is the best percentage change in tumour size from baseline using RECIST v1.1 tumour response.

Time frame:
At baseline and every 6 weeks from time of first dose until date of progression, up to 24 months after LPFD.
Reported as:
Mean · % change from baseline in target lesion
Tumour Shrinkage According to RECIST 1.1 by Independent Review
% change from baseline in target lesionAZD9291
Tumour Shrinkage According to RECIST 1.1 by Independent Review-46.1 ± 28.40
SecondaryPFS According to RECIST 1.1 by Independent Review

Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Progressive Disease (PD): \>= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of \>=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. PFS is the time from date of first dose until the date of PD (by independent review) or death (by any cause in the absence of progression) regardless of whether the patient withdrew from AZD9291 therapy or received another anti-cancer therapy prior to progression. Patients who had not progressed or died at the time of analysis were censored at the time of the latest date of assessment from their last evaluable RECIST 1.1 assessment.

Time frame:
At baseline and every 6 weeks from time of first dose until objective disease progression, up to 24 months after LPFD.
Reported as:
Median · Months
PFS According to RECIST 1.1 by Independent Review
MonthsAZD9291
PFS According to RECIST 1.1 by Independent Review9.7 (7.0 to 11.1)
SecondaryOverall Survival (OS)

Defined as the time from first dose until death from any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.

Time frame:
From first dose to end of study or date of death from any cause, whichever comes first, assessed every 6 weeks up to approximately 95 OS events (about 55% maturity) have been observed out of all enrolled patients.
Reported as:
Median · Months
Overall Survival (OS)
MonthsAZD9291
Overall Survival (OS)23.2 (20.0 to 26.7)

Adverse events

Collected over AEs were collected from time of signature of informed consent throughout the treatment period and including the 28-day safety follow-up after the last dose of the study treatment, approximately 33 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AZD9291 80mg11/171 (6.4%)42/171 (24.6%)163/171 (95.3%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventAZD9291 80mg
PneumoniaInfections and infestations4/171
Lung infectionInfections and infestations3/171
DyspnoeaRespiratory, thoracic and mediastinal disorders3/171
Pericardial effusionCardiac disorders2/171
Upper respiratory tract infectionInfections and infestations2/171
Respiratory failureRespiratory, thoracic and mediastinal disorders2/171
Deep vein thrombosisVascular disorders2/171
Sudden deathGeneral disorders1/171
BronchitisInfections and infestations1/171
TuberculosisInfections and infestations1/171
Most frequent other events
Showing 10 of 39
Most frequent other events
EventAZD9291 80mg
DiarrhoeaGastrointestinal disorders60/171
CoughRespiratory, thoracic and mediastinal disorders42/171
LeukopeniaBlood and lymphatic system disorders36/171
Platelet count decreasedInvestigations31/171
White blood cell count decreasedInvestigations30/171
Upper respiratory tract infectionInfections and infestations28/171
Dry skinSkin and subcutaneous tissue disorders26/171
PruritusSkin and subcutaneous tissue disorders26/171
AnaemiaBlood and lymphatic system disorders25/171
ThrombocytopeniaBlood and lymphatic system disorders25/171

Baseline characteristics

All patients enrolled who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(Years)AZD9291
Mean58.3 ± 10.81
Age, Customized
Age, Customized(Participants)AZD9291
<50 Years38
>=50-<65 Years79
>=65-<75 Years45
>=75 Years9
Sex: Female, Male
Sex: Female, Male(Participants)AZD9291
Female117
Male54
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AZD9291
Asian168
White2
Other1
08

Study locations

30 sites
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    Nedlands, 6009, Australia
  • Research Site
    Woolloongabba, 4102, Australia
  • Research Site
    Beijing, 100021, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Changchun, 130000, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chongqing, 400038, China
  • Research Site
    Chongqing, 400042, China
  • Research Site
    Fuzhou, 350014, China
  • Research Site
    Haikou, 570311, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310006, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150049, China
  • Research Site
    Jinan, 250117, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Shanghai, 200030, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, CN-200433, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Xi'an, 710032, China
  • Research Site
    Xi'an, 710038, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Goyang-si, 10408, South Korea
  • Research Site
    Seongnam-si, 13620, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 6351, South Korea
09

References and documents

Related links

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Mar 2016, 8 months.

Results were first posted in Apr 2017, 1 year 1 month after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 8 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2015
First posted
May 13, 2015
StartActual
Jun 22, 2015
Primary completionActual
Mar 4, 2016
CompletionActual
Nov 28, 2025
Results first posted
Apr 25, 2017
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02442349
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 13, 2015
Start date
Jun 22, 2015
Primary completion
Mar 4, 2016
Completion
Nov 28, 2025
Results posted
Apr 25, 2017
Last update
Jan 9, 2026

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion